Table 1 Clinical presentations and demographic data of the RA patients and healthy controls
From: Prevalence and contributing factors of metabolic syndrome in rheumatoid arthritis patients
Characteristic | RA patients (n = 500) | Healthy controls (n = 500) | P value |
|---|---|---|---|
Gender (Female, %) | 365 (73%) | 360 (72%) | 0.347 |
Age (Year, mean ± SD) | 52.1 ± 13.3 | 51.4 ± 12.7 | 0.144 |
Disease duration (Year, mean ± SD) | 13.2 ± 7.6 | - | - |
28Tender Joint Count (mean ± SD) | 3.01 ± 2.14 | - | - |
28Swollen Joint Count (mean ± SD) | 2.74 ± 2.04 |  |  |
DAS28 (mean ± SD) | 3.38 ± 1.36 | - | - |
Hypertension (Yes, %) | 215 (43%) | 105 (21%) | < 0.0001 |
RF (IU/ml, mean ± SD) | 32.5 ± 9.6 | - |  |
Anti-CCP (IU/ml, mean ± SD) | 37.3 ± 11.8 | - |  |
CRP (IU/ml, mean ± SD) | 36.12 ± 12.64 | - |  |
ESR (mm/h, mean ± SD) | 21.3 ± 14.9 | 4.7 ± 2.1 | < 0.0001 |
T2DM (Yes, %) | 89 (17.8%) | - | Â |
Smoker (Yes, %) | 219 (43.8%) | 216 (43.2%) | 0.848 |
History of CVD (Yes, %) | 49 (9.8%) | 23 (4.6%) | 0.0019 |
Familial history of CVD | 53 (10.6%) | 24 (4.8%) | 0.0032 |
BMI (kg/m2, mean ± SD) | 28.3 ± 4.9 | 24.8 ± 2.9 | 0.024 |
WC-Male (cm, mean ± SD) | 106.4 ± 9.1 | 96.2 ± 7.9 | < 0.001 |
WC-Female (cm, mean ± SD) | 95.4 ± 8.9 | 85.6 ± 7.7 | < 0.001 |
Dyslipidemia (Yes, %) | 214 (42.8%) | 201 (40.2%) | 0.404 |
Total cholesterol (mg/dl, mean ± SD) | 195.8 ± 41.8 | 165.6 ± 38.4 | 0.001 |
FBS (mg/dl, mean ± SD) | 94.3 ± 34.2 | 86.4 ± 21.8 | 0.011 |
TG (mg/dl, mean ± SD) | 154.9 ± 62.5 | 134.8 ± 41.3 | 0.048 |
LDL (mg/dl, mean ± SD) | 121.9 ± 36.8 | 118.5 ± 32.7 | 0.122 |
HDL-Male (mg/dl, mean ± SD) | 46.2 ± 13.1 | 53.3 ± 13.5 | 0.033 |
HDL-Female (mg/dl, mean ± SD) | 45.5 ± 14.2 | 55.9 ± 15.1 | 0.013 |
MetS (Yes, %) | 294 (58.8%) | 102 (20.4%) | < 0.0001 |
Use of prednisolone (Yes, %) | 388 (77.6%) | Â | - |
Use of methotrexate (Yes, %) | 397 (79.4%) | Â | - |
Use of biologics (Yes, %) | 84 (16.8%) | Â | - |